Emmanuel Papadakis
Stock Analyst at Deutsche Bank
(1.92)
# 2,988
Out of 4,734 analysts
41
Total ratings
47.37%
Success rate
1.88%
Average return
Main Sectors:
Stocks Rated by Emmanuel Papadakis
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BNTX BioNTech SE | Maintains: Buy | $95 → $150 | $111.93 | +34.01% | 9 | Sep 19, 2024 | |
| MRNA Moderna | Upgrades: Hold | $85 → $80 | $34.06 | +134.88% | 8 | Aug 6, 2024 | |
| GRFS Grifols | Downgrades: Sell | n/a | $7.27 | - | 2 | Mar 12, 2024 | |
| AZN AstraZeneca | Downgrades: Hold | n/a | $66.60 | - | 3 | Feb 8, 2024 | |
| ALVO Alvotech | Maintains: Hold | $8 → $12 | $13.27 | -9.57% | 2 | Mar 7, 2023 | |
| SNY Sanofi | Upgrades: Hold | n/a | $50.74 | - | 4 | Aug 12, 2022 | |
| NVO Novo Nordisk | Upgrades: Buy | n/a | $78.69 | - | 4 | Mar 16, 2022 | |
| CVAC CureVac | Initiates: Hold | $35 | $4.10 | +753.66% | 1 | Oct 22, 2021 | |
| NVS Novartis AG | Downgrades: Sell | n/a | $97.53 | - | 3 | Sep 20, 2021 | |
| ARGX argenx SE | Initiates: Hold | n/a | $640.52 | - | 1 | Jul 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | n/a | $33.43 | - | 4 | Feb 4, 2021 |
BioNTech SE
Sep 19, 2024
Maintains: Buy
Price Target: $95 → $150
Current: $111.93
Upside: +34.01%
Moderna
Aug 6, 2024
Upgrades: Hold
Price Target: $85 → $80
Current: $34.06
Upside: +134.88%
Grifols
Mar 12, 2024
Downgrades: Sell
Price Target: n/a
Current: $7.27
Upside: -
AstraZeneca
Feb 8, 2024
Downgrades: Hold
Price Target: n/a
Current: $66.60
Upside: -
Alvotech
Mar 7, 2023
Maintains: Hold
Price Target: $8 → $12
Current: $13.27
Upside: -9.57%
Sanofi
Aug 12, 2022
Upgrades: Hold
Price Target: n/a
Current: $50.74
Upside: -
Novo Nordisk
Mar 16, 2022
Upgrades: Buy
Price Target: n/a
Current: $78.69
Upside: -
CureVac
Oct 22, 2021
Initiates: Hold
Price Target: $35
Current: $4.10
Upside: +753.66%
Novartis AG
Sep 20, 2021
Downgrades: Sell
Price Target: n/a
Current: $97.53
Upside: -
argenx SE
Jul 23, 2021
Initiates: Hold
Price Target: n/a
Current: $640.52
Upside: -
Feb 4, 2021
Downgrades: Sell
Price Target: n/a
Current: $33.43
Upside: -